AstraZeneca PLC Puts up a Fight Against Scottish Medicines Consortium’s Iressa Rejection

Pharma Times -- AstraZeneca’s cancer drug Iressa has suffered a further setback in the UK after cost regulators rejected its use on NHS Scotland as a treatment for patients with non-small cell lung cancer.